VIENNA—Three key targetable pathways for breast cancer treatment were assessed at the St Gallen Breast Cancer Conference by Clifford Hudis, MD, Chief of the Breast Medicine Service at Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York. He gave Oncology Times reporter Sarah Maxwell his review of the clinical usefulness of targeting the CDK 4-6, PIK3CA and FGFR pathways.
Targeting Emerging Drugable Pathways in Breast Cancer—Clinical Potential Assessed
Further reading
The microbiome is emerging as a powerful ally to cancer doctors to harness in tandem with curative therapies, especially with allogeneic stem cell...
Bi-specific T-cell engager promise in B-cell acute lymphoblastic leukemia
Single cell transcriptome analysis yields details of molecular features that promise to help customise therapy for each individual patient.
Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant...
Babies Use Object Permanence To Get What They Want 2022: A report from the journal: Pediatric Physical Therapy Regina Harbourne PhD, PT, PCS, FAPTA...
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...